Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver
Max Preti, … , Antonella Carambia, Johannes Herkel
Max Preti, … , Antonella Carambia, Johannes Herkel
Published February 18, 2021
Citation Information: JCI Insight. 2021;6(6):e141462. https://doi.org/10.1172/jci.insight.141462.
View: Text | PDF
Research Article Hepatology

Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver

  • Text
  • PDF
Abstract

The liver is an immune-privileged organ that can deactivate autoreactive T cells. Yet in autoimmune hepatitis (AIH), autoreactive T cells can defy hepatic control and attack the liver. To elucidate how tolerance to self-antigens is lost during AIH pathogenesis, we generated a spontaneous mouse model of AIH, based on recognition of an MHC class II–restricted model peptide in hepatocytes by autoreactive CD4+ T cells. We found that the hepatic peptide was not expressed in the thymus, leading to deficient thymic deletion and resulting in peripheral abundance of autoreactive CD4+ T cells. In the liver, autoreactive CD4+ effector T cells accumulated within portal ectopic lymphoid structures and maturated toward pathogenic IFN-γ and TNF coproducing cells. Expansion and pathogenic maturation of autoreactive effector T cells was enabled by a selective increase of plasticity and instability of autoantigen-specific Tregs but not of nonspecific Tregs. Indeed, antigen-specific Tregs were reduced in frequency and manifested increased IL-17 production, reduced epigenetic demethylation, and reduced expression of Foxp3. As a consequence, autoantigen-specific Tregs had a reduced suppressive capacity, as compared with that of nonspecific Tregs. In conclusion, loss of tolerance and the pathogenesis of AIH were enabled by combined failure of thymic deletion and peripheral regulation.

Authors

Max Preti, Lena Schlott, David Lübbering, Daria Krzikalla, Anna-Lena Müller, Fenja A. Schuran, Tobias Poch, Miriam Schakat, Sören Weidemann, Ansgar W. Lohse, Christina Weiler-Normann, Marcial Sebode, Dorothee Schwinge, Christoph Schramm, Antonella Carambia, Johannes Herkel

×

Figure 2

Spontaneous development of AIH features in Alb-iGP_Smarta mice.

Options: View larger image (or click on image) Download as PowerPoint
Spontaneous development of AIH features in Alb-iGP_Smarta mice.
(A) Spon...
(A) Spontaneous development of sickness symptoms, shown as age-dependently reduced percentage of symptom-free Alb-iGP_Smarta mice (red line; n = 12), compared with Alb-iGP control mice (blue line; n = 13) and Itgax-iGP_Smarta control mice (pink line; n = 10). (B) Serum ALT and AST (each U/l; n = 8–9) in Alb-iGP_Smarta mice at early or late disease stage, and Alb-iGP control mice. (C) Representative histology of 2 Alb-iGP_Smarta livers in early disease stage, showing periportal infiltrates (top), or late disease stage (bottom), showing periportal and interface hepatitis with mainly lymphocytic infiltrates (original magnification, ×100). (D) The mHAI score (n = 4–13) of Alb-iGP_Smarta livers (early and late disease) and Alb-iGP control livers. (E) Serum IgG levels (g/ml; n = 5–9). (F) Hepatic CD19+CD138+ plasma cells (n = 4–5). (G) Antinuclear antibody (ANA) titers (n = 4–11) and representative fluorographs. Data are shown as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (A, Mantel-Cox; B, D, and E, ANOVA; F, Fisher’s exact test).

Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts